AL
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $22M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Alkermes plc (ALKS) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for ALKS — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 38.50 | NEUTRAL |
| Stochastic %K (14) | 29.90 | NEUTRAL |
| CCI (20) | -124.41 | BUY |
| Williams %R (14) | -70.10 | NEUTRAL |
| MACD (12,26,9) | -0.25 | SELL |
| ROC (10) | -6.20 | SELL |
| Momentum (10) | -3.05 | SELL |
| EMA (10) | 46.74 | SELL |
| SMA (10) | 46.82 | SELL |
| EMA (20) | 47.64 | SELL |
| SMA (20) | 47.99 | SELL |
| EMA (30) | 48.11 | SELL |
| SMA (30) | 48.47 | SELL |
| EMA (50) | 47.93 | SELL |
| SMA (50) | 50.11 | SELL |
| EMA (100) | 45.20 | BUY |
| SMA (100) | 45.18 | BUY |
| EMA (200) | 39.63 | BUY |
| SMA (200) | 37.97 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Background via Yahoo Finance — informational, not part of the verdict.
🔴 AVOID
The main driver: lagging the market by 8.2%, insider selling on the open market. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.
Scores: 1 bullish / 3 bearish
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Peer movement computing — it will appear here on its own.
CLUSTER SELL 0 buys · 7 sells
Recent: Gaffin David Joseph sold 227490 sh @ $54.03 (2026-07-06); Gaffin David Joseph sold 225456 sh @ $48.58 (2026-08-03); Hopkinson Craig C. sold 73389 sh @ $52.13 (2026-07-01)
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
